CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

我如何治疗浆细胞白血病

How I treat plasma cell leukemia.

靶向 BCMA 和 GPRC5D 的双特异性抗体治疗浆细胞白血病的真实世界结局

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

全人源抗 GPRC5D CAR-T 细胞疗法 RD118 在复发/难治性多发性骨髓瘤中诱导持久缓解

The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma.

多发性骨髓瘤的序贯靶向治疗：GPRC5D 双特异性抗体 talquetamab 作为 BCMA CAR-T 治疗的桥接

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

抗 BCMA CAR-T 细胞与靶向 GPRC5D 双特异性抗体治疗后的 T 细胞淋巴瘤多组学分析

Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody.

多发性骨髓瘤中 T 细胞重定向治疗的皮肤毒性：EADV 工作组立场文件与实践建议

Cutaneous Toxicities of T-Cell-Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations.

多发性骨髓瘤免疫治疗序贯的真实世界证据：既往 GPRC5D 靶向治疗后 BCMA 靶向双特异性抗体可带来持久缓解

Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5

靶向 BCMA 的双特异性抗体为经靶向 GPRC5D 的双特异性抗体治疗后进展的患者提供了一种有效且耐受性良好的治疗选择，支持该序贯方案作为一种有前景策略的可行性。

抗 BCMA 与 GPRC5D 双特异性抗体治疗复发/难治性原发性浆细胞白血病：一例病例报告

Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report.

SOHO 最新进展与后续问题 | 骨髓瘤早期复发的治疗：非 CAR-T 细胞

SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell.